TG Therapeutics, Inc. (TGTX) Financial Statements
TG Therapeutics, Inc. (TGTX) reported trailing twelve-month revenue of $799.5M (up 76.1% year on year) and net income of $441.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $17.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TGTXTG Therapeutics, Inc.Follow TGTX — free
—
Price chart with a free account
- Market cap
- 8.3B
- P/E TTM
- 19.7
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.23 | 0.33 | 0.62 | 0.80 | |
| Gross profit | — | — | — | — | — | 0.22 | 0.29 | 0.52 | 0.66 | |
| Research & development | 0.16 | 0.15 | 0.17 | 0.22 | 0.13 | 0.08 | 0.09 | 0.16 | 0.23 | |
| Operating income | -0.17 | -0.17 | -0.27 | -0.34 | -0.22 | 0.02 | 0.04 | 0.12 | 0.14 | |
| Pre-tax income | -0.00 | -0.17 | -0.28 | -0.35 | -0.22 | 0.01 | 0.03 | 0.11 | 0.10 | |
| Income tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.34 | -0.34 | |
| Net income | -0.17 | -0.17 | -0.28 | -0.35 | -0.22 | 0.01 | 0.02 | 0.45 | 0.44 | |
| Diluted EPS ($) | -2.30 | -1.96 | -2.42 | -2.63 | -1.65 | 0.09 | 0.15 | 2.77 | 2.75 | |
| Diluted shares (bn) | — | — | — | — | 0.135 | 0.149 | 0.160 | 0.161 | — |
USD billions · SEC XBRL
TG Therapeutics, Inc. — questions
- What is TG Therapeutics, Inc.'s revenue?
- $799.5M over the twelve months to 2026-06-30, up 76.1% year on year, from its 10-Q and 10-K filings.
- What is TG Therapeutics, Inc.'s net income?
- $441.5M over the twelve months to 2026-06-30.
- What is TG Therapeutics, Inc.'s free cash flow?
- $17.4M over the twelve months to 2026-06-30.
- What are TG Therapeutics, Inc.'s diluted earnings per share?
- $2.75 over the twelve months to 2026-06-30.
Every figure on this page comes from TG Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.